Patent US4191699A successfully refreshed from Google Patents.
US4191699A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Various- 15-deoxy-16-hydroxy-16-ethynyl and 16-ethynylsubstituted prostaglandins
Assignee: Wyeth Holdings LLC
•
Filing: 1977-12-05
•
Granted: 1980-03-04
•
Expires: 1997-12-05
Abstract
Abstract 15-Deoxy-16-hydroxy-16-ethynyl and 16-ethynylsubstituted prostanoic acids and congeners thereof, useful as bronchodilators, hypotensive agents, and as agents for the control of excessive gastric secretion.
Inventors
- 👤 Middleton B. Floyd, Jr.
- 👤 Martin J. Weiss
- 👤 Charles V. Grudzinskas
- 👤 Sow-mei L. Chen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 13:01
CPC Classifications
C; C07; C07D; C07D307/00; C07D307/02; C07D307/34; C07D307/38; C07D307/40; C07D307/42; C07C; C07C29/00; C07C29/09; C07C29/10; C07C29/36; C07C29/38; C07C29/42; C07C405/00; C07C405/0008; C07C405/0025; C07C405/0033; C07C45/00; C07C45/27; C07C45/29; C07C49/00; C07C49/20; C07C49/227; C07C49/587; C07C49/703; C07C49/743; C07C49/753; C07F; C07F7/00; C07F7/02; C07F7/08; C07F7/18; C07F7/1804; C07F7/22; C07F7/2208
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
121 words
An optically active compound of the formula: ##STR24## wherein Y is a divalent moiety of the formula: ##STR25## R 1 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; R 2 is selected from the group consisting of C 3 to C 7 alkyl; R 3 is selected from the group consisting of hydrogen and hydroxy; X is selected from the group consisting of a divalent moiety of the formula: ##STR26## wherein R 5 is selected from the group consisting of 1-propenyl, ethynyl and trimethyl-silylethynyl; Z is selected from the group consisting of a divalent moiety of the formula: ##STR27## the racemic mixture thereof; and, when R 1 is hydrogen, the pharmacologically acceptable salts thereof.
Claim 2
Dependent Claim
121 words
An optically active compound of the formula: ##STR24## wherein Y is a divalent moiety of the formula: ##STR25## R 1 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; R 2 is selected from the group consisting of C 3 to C 7 alkyl; R 3 is selected from the group consisting of hydrogen and hydroxy; X is selected from the group consisting of a divalent moiety of the formula: ##STR26## wherein R 5 is selected from the group consisting of 1-propenyl, ethynyl and trimethyl-silylethynyl; Z is selected from the group consisting of a divalent moiety of the formula: ##STR27## the racemic mixture thereof; and, when R 1 is hydrogen, the pharmacologically acceptable salts thereof.
Claim 3
Dependent Claim
121 words
An optically active compound of the formula: ##STR28## wherein Y is a divalent moiety of the formula: ##STR29## R 1 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; R 2 is selected from the group consisting of C 3 to C 7 alkyl; R 3 is selected from the group consisting of hydrogen and hydroxy; X is selected from the group consisting of a divalent moiety of the formula: ##STR30## wherein R 5 is selected from the group consisting of 2-propynyl, ethynyl and trimethylsilylethynyl; Z is selected from the group consisting of a divalent moiety of the formula: ##STR31## the racemic mixture thereof; and, when R 1 is hydrogen, the pharmacologically acceptable salts thereof.
Claim 4
Dependent Claim
121 words
An optically active compound of the formula: ##STR28## wherein Y is a divalent moiety of the formula: ##STR29## R 1 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; R 2 is selected from the group consisting of C 3 to C 7 alkyl; R 3 is selected from the group consisting of hydrogen and hydroxy; X is selected from the group consisting of a divalent moiety of the formula: ##STR30## wherein R 5 is selected from the group consisting of 2-propynyl, ethynyl and trimethylsilylethynyl; Z is selected from the group consisting of a divalent moiety of the formula: ##STR31## the racemic mixture thereof; and, when R 1 is hydrogen, the pharmacologically acceptable salts thereof.
Claim 5
Dependent Claim
11 words
A compound according to claim 1, wherein R 3 is hydroxyl.
Claim 6
Dependent Claim
11 words
A compound according to claim 1, wherein R 3 is hydrogen.
Claim 7
Dependent Claim
11 words
The optically active compound according to claim 3, nat. 9α,11α,16-trihydroxy-16-ethynyl-5-cis,13-trans-prostadienoic acid.
Claim 8
Dependent Claim
10 words
The optically active compound according to claim 3, nat. methyl-9α,11α,16-trihydroxy-16-ethynyl-20-ethyl-5-cis,13-trans-prostadienoate.
Claim 9
Dependent Claim
10 words
The optically active compound according to claim 3, nat. methyl-9α,11α,16-trihydroxy-16-(1-propynyl)-5-cis,13-trans-prostadienoate.
Claim 10
Dependent Claim
11 words
The optically active compound according to claim 3, nat. 9α,11α,16-trihydroxy-16-(1-propynyl)-20-ethyl-5-cis,13-trans-prostadienoic acid.
Claim 11
Dependent Claim
11 words
The optically active compound according to claim 3, nat. 9α,11α,16-trihydroxy-16-trimethylsilylethynyl-5-cis,13-trans-prostadienoic acid.
Claim 12
Dependent Claim
10 words
The optically active compound according to claim 3, nat. hexyl-9α,11α,16-trihydroxy-16-trimethylsilylethynyl-20-ethyl-5-cis,13-trans-prostadienoate.
Claim 13
Dependent Claim
8 words
The racemic compound according to claim 3, dl-methyl-9α,11α,16-trihydroxy-16-ethynyl-5-cis,13-trans-prostadienoate.
Claim 14
Dependent Claim
9 words
The racemic compound according to claim 3, dl-9α,11α,16-trihydroxy-16-ethynyl-20-ethyl-5-cis,13-trans-prostadienoic acid.
Claim 15
Dependent Claim
9 words
The racemic compound according to claim 3, dl-9α,11α,16-trihydroxy-16-(1-propenyl)-5-cis,13-trans-prostadienoic acid.
Claim 16
Dependent Claim
8 words
The racemic compound according to claim 3, dl-hexyl-9α,11α,16-trihydroxy-16-(1-propenyl)-20-ethyl-5-cis,13-trans-prostadienoate.
Claim 17
Dependent Claim
8 words
The racemic compound according to claim 3, dl-methyl-9α,11α,16-trihydroxy-16-(1-propynyl)-20-ethyl-5-cis,13-trans-prostadienoate.
Claim 18
Dependent Claim
8 words
The racemic compound according to claim 3, dl-9α,11α,16-trihydroxy-16-trimethylsilylethynyl-20-ethyl-5-cis,13-trans-prostadienoate.
Claim 19
Dependent Claim
11 words
A compound according to claim 2, wherein R 3 is hydroxyl.
Claim 20
Dependent Claim
10 words
The optically active compound according to claim 17, nat. methyl-9β,11α,16-trihydroxy-16-ethynyl-5-cis,13-trans-prostadienoate.
Claim 21
Dependent Claim
11 words
The optically active compound according to claim 17, nat. 9β,11α,16-trihydroxy-16-ethynyl-20-ethyl-5-cis,13-trans-prostadienoic acid.
Claim 22
Dependent Claim
11 words
The optically active compound according to claim 17, nat. 9β,11α,16-trihydroxy-16-(1-propynyl)-5-cis,13-trans-prostadienoic acid.
Claim 23
Dependent Claim
10 words
The optically active compound according to claim 17, nat. methyl-9β,11α,16-trihydroxy-16-(1-propynyl)-20-ethyl-5-cis,13-trans-prostadienoate.
Claim 24
Dependent Claim
10 words
The optically active compound according to claim 17, nat. methyl-9β,11α,16-trihydroxy-16-trimethylsilylethynyl-5-cis,13-trans-prostadienoate.
Claim 25
Dependent Claim
11 words
The optically active compound according to claim 17, nat. 9β,11α,16-trihydroxy-16-trimethylsilylethynyl-20-ethyl-5-cis,13-trans-prostadienoic acid.
Claim 26
Dependent Claim
9 words
The racemic compound according to claim 17, dl-9β,11α,16-trihydroxy-16-ethynyl-5-cis,13-trans-prostadienoic acid.
Claim 27
Dependent Claim
8 words
The racemic compound according to claim 17, dl-methyl-9β,11α,16-trihydroxy-16-ethynyl-20-ethyl-5-cis,13-trans-prostadienoate.
Claim 28
Dependent Claim
8 words
The racemic compound according to claim 17, dl-methyl-9β,11α,16-trihydroxy-16-(1-propynyl)-5-cis,13-trans-prostadienoate.
Claim 29
Dependent Claim
9 words
The racemic compound according to claim 17, dl-9β,11α,16-trihydroxy-16-(1-propynyl)-20-ethyl-5-cis,13-trans-prostadienoic acid.
Claim 30
Dependent Claim
9 words
The racemic compound according to claim 17, dl-9β,11α,16-trihydroxy-16-trimethylsilylethynyl-5-cis,13-trans-prostadienoic acid.
Claim 31
Dependent Claim
8 words
The racemic compound according to claim 17, dl-methyl-9β,11α,16-trihydroxy-16-trimethylsilylethynyl-20-ethyl-5-cis,13-trans-prostadienoate.
References Cited (Backward Citations)
US3965143A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-03-04 | 1983-09-03 | 1984-03-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-03-04 | 1987-09-03 | 1988-03-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-03-04 | 1991-09-03 | 1992-03-04 | $7700.00 | Window Closed / Lapsed |